On Friday, iTeos TherapeuticsITOS got a positive adjustment to its Relative Strength (RS) Rating, from 70 to 76. Please watch the video at Investors.com - How To Trade Options: Choosing The Right ...

Dollar General set a quarterly sales record of $10.44 billion and upgraded its annual profit and sales outlook as Americans tighten their budgets and spend more at bargain stores and off-price ...

Novartis launched a tender offer for Regulus Therapeutics. Biogen and City Therapeutics announced a partnership to develop a drug for an undisclosed central nervous system disease. Eli Lilly bought ...

Teos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Detailed price information for Iteos Therapeutics Inc (ITOS-Q) from The Globe and Mail including charting and trades.

Teos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.

By Kamal Choudhury (Reuters) -ITeos Therapeutics plans to wind down its operations and sell its assets, including experimental cancer treatments and an obesity drug, the company said on Wednesday, two ...

WATERTOWN, Mass. – iTeos Therapeutics, Inc. (NASDAQ:ITOS), una compañía biofarmacéutica en fase clínica con una capitalización de mercado de 326 millones de dólares, anunció hoy su plan ...

iTeos Therapeutics (NASDAQ:ITOS) added ~25% in the premarket on Wednesday after the immuno-oncology drug developer announced plans to wind down operations as an outcome of a strategic review aimed ...

WATERTOWN, Mass. and GOSSELIES, Belgium, May 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

ITeos Therapeutics is throwing in the towel. Two weeks after axing its GSK-partnered TIGIT candidate, the biotech has decided to wind down operations, sell its assets and return as much of its $ ...